微RNA调控卵巢癌顺铂耐药的机制研究进展

doi:10.3760/cma.j.cn371439-20231109-00030

摘要/Abstract

摘要：

顺铂耐药是卵巢癌患者治疗效果不佳的重要因素。微RNA（miRNA）可通过调控细胞结构分子、DNA修复与细胞周期、凋亡和Wnt/β-catenin信号通路、自噬、甲基化和肿瘤干细胞，参与调控卵巢癌顺铂耐药。进一步了解miRNA调控卵巢癌顺铂耐药的机制，有助于寻找新的治疗方式，以优化现有治疗方案，提高疗效。

关键词: 卵巢肿瘤, 微RNAs, 顺铂, 抗药性, 肿瘤

Abstract:

Cisplatin resistance is an important factor in the poor treatment effect of ovarian cancer patients. MicroRNA （miRNA） can regulate cellular structural molecules， DNA repair， cell cycle， apoptosis and Wnt/β-catenin signaling pathway， autophagy， methylation and cancer stem cell， which are involved in the regulation of cisplatin resistance in ovarian cancer. Further understanding the mechanism of miRNA regulation of cisplatin resistance in ovarian cancer will help find new treatment options to optimize existing treatment plans and improve efficacy.

Key words: Ovarian neoplasms, MicroRNAs, Cisplatin, Drug resistance, neoplasm

龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.

Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.

参考文献 46

[1]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[2]	Dou L, Zhang Y. MiR-4461 regulates the proliferation and metastasis of ovarian cancer cells and cisplatin resistance[J]. Front Oncol, 2021, 11: 614035. DOI: 10.3389/fonc.2021.614035.
[3]	Biamonte F, Santamaria G, Sacco A, et al. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer[J]. Sci Rep, 2019, 9(1): 5668. DOI: 10.1038/s41598-019-42221-x. pmid: 30952937
[4]	Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer[J]. Eur J Med Chem, 2022, 232: 114205. DOI: 10.1016/j.ejmech.2022.114205.
[5]	Wang Z, Zhou X, Deng X, et al. MiR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer[J]. Front Oncol, 2023, 13: 1166666. DOI: 10.3389/fonc.2023.1166666.
[6]	Kou X, Ding H, Li L, et al. Hsa-miR-105-1 regulates cisplatin-resistance in ovarian carcinoma cells by targeting ANXA9[J]. Anal Cell Pathol (Amst), 2021, 2021: 6662486. DOI: 10.1155/2021/6662486.
[7]	Arora S, Heyza JR, Chalfin EC, et al. Gap junction intercellular communication positively regulates cisplatin toxicity by inducing DNA damage through bystander signaling[J]. Cancers (Basel), 2018, 10(10): 368. DOI: 10.3390/cancers10100368.
[8]	Yu X, Zhang X, Wang G, et al. MiR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer[J]. Cancer Cell Int, 2020, 20(1): 534. DOI: 10.1186/s12935-020-01623-y. pmid: 33292230
[9]	Lin L, Wu Q, Lu F, et al. Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers[J]. Front Oncol, 2023, 13: 1184079. DOI: 10.3389/fonc.2023.1184079.
[10]	Huang W, Chen L, Zhu K, et al. Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin[J]. Cell Death Discov, 2021, 7(1): 379. DOI: 10.1038/s41420-021-00715-6. pmid: 34876558
[11]	Wu J, Bao L, Zhang Z, et al. Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells[J]. Oncotarget, 2017, 8(55): 93502-93515. DOI: 10.18632/oncotarget.19548. pmid: 29212168
[12]	Wu J, Zhang L, Wu S, et al. MiR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer[J]. Pathol Res Pract, 2020, 216(7): 152979. DOI: 10.1016/j.prp.2020.152979.
[13]	Li B, Xu X, Zheng L, et al. MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer[J]. Mol Biol Rep, 2023, 50(8): 6819-6827. DOI: 10.1007/s11033-023-08599-8. pmid: 37392283
[14]	Wang T, Hao D, Yang S, et al. MiR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer[J]. Cell Death Dis, 2019, 10(7): 495. DOI: 10.1038/s41419-019-1715-x. pmid: 31235732
[15]	Wang J, Liu L. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A[J]. J Ovarian Res, 2021, 14(1): 165. DOI: 10.1186/s13048-021-00919-5. pmid: 34798882
[16]	Guo H, Ha C, Dong H, et al. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A[J]. Cancer Cell Int, 2019, 19: 347. DOI: 10.1186/s12935-019-1051-3. pmid: 31889899
[17]	Wang Y, Yan C, Qi J, et al. MiR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells[J]. Mol Cell Biochem, 2022, 477(1): 307-317. DOI: 10.1007/s11010-021-04271-6.
[18]	Li X, Chen W, Jin Y, et al. MiR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes[J]. Biochem Pharmacol, 2019, 161: 98-112. DOI: 10.1016/j.bcp.2019.01.009. pmid: 30639456
[19]	Todeschini P, Salviato E, Romani C, et al. Comprehensive profiling of hypoxia-related miRNAs identifies miR-23a-3p overexpression as a marker of platinum resistance and poor prognosis in high-grade serous ovarian cancer[J]. Cancers (Basel), 2021, 13(13): 3358. DOI: 10.3390/cancers13133358.
[20]	Xiang Y, Chen YJ, Yan YB, et al. MiR-186 bidirectionally regulates cisplatin sensitivity of ovarian cancer cells via suppres-sing targets PIK3R3 and PTEN and upregulating APAF1 expression[J]. J Cancer, 2020, 11(12): 3446-3453. DOI: 10.7150/jca.41135. pmid: 32284740
[21]	Belur Nagaraj A, Knarr M, Sekhar S, et al. The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer[J]. Cancer Res, 2021, 81(8): 2044-2055. DOI: 10.1158/0008-5472.CAN-20-2041. pmid: 33574092
[22]	Liu HR, Zhao J. Effect and mechanism of miR-217 on drug resistance, invasion and metastasis of ovarian cancer cells through a regulatory axis of CUL4B gene silencing/inhibited Wnt/β-catenin signaling pathway activation[J]. Eur Rev Med Pharmacol Sci, 2021, 25(1): 94-107. DOI: 10.26355/eurrev_202101_24353.
[23]	Ge T, Liu T, Guo L, et al. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma[J]. Exp Cell Res, 2020, 396(1): 112241. DOI: 10.1016/j.yexcr.2020.112241.
[24]	Xiao S, Li Y, Pan Q, et al. MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy[J]. J Cell Biochem, 2019, 120(3): 2940-2953. DOI: 10.1002/jcb.26865. pmid: 30537410
[25]	Zhang XY, Li YF, Ma H, et al. Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis[J]. Sci Rep, 2020, 10(1): 6893. DOI: 10.1038/s41598-020-63396-8.
[26]	Sun Y, Wu J, Dong X, et al. MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers[J]. Transl Oncol, 2021, 14(2): 100987. DOI: 10.1016/j.tranon.2020.100987.
[27]	Campos Gudiño R, McManus KJ, Hombach-Klonisch S. Aberrant HMGA2 expression sustains genome instability that promotes metastasis and therapeutic resistance in colorectal cancer[J]. Cancers (Basel), 2023, 15(6): 1735. DOI: 10.3390/cancers15061735.
[28]	Song Z, Liao C, Yao L, et al. MiR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signa-ling and autophagy via targeting HMGA2[J]. Cancer Gene Ther, 2023, 30(4): 596-607. DOI: 10.1038/s41417-022-00574-y.
[29]	Zhou Y, Wang C, Ding J, et al. MiR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy[J]. Cancer Cell Int, 2022, 22(1): 15. DOI: 10.1186/s12935-021-02412-x. pmid: 35012539
[30]	Cai Y, An B, Yao D, et al. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy[J]. Bioengineered, 2021, 12(2): 10713-10722. DOI: 10.1080/21655979.2021.2001989. pmid: 34747309
[31]	Hu Z, Cai M, Zhang Y, et al. MiR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway[J]. Cell Cycle, 2020, 19(2): 193-206. DOI: 10.1080/15384101.2019.1704537. pmid: 31885310
[32]	Yu JL, Gao X. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4): 1688-1696. DOI: 10. 26355/eurrev_202002_20343.
[33]	Han X, Liu D, Zhou Y, et al. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer[J]. Cell Biol Int, 2021, 45(1): 227-237. DOI: 10.1002/cbin.11486. pmid: 33090550
[34]	Li H, Lei Y, Li S, et al. MicroRNA-20a-5p inhibits the autophagy and cisplatin resistance in ovarian cancer via regulating DNMT3B-mediated DNA methylation of RBP1[J]. Reprod Toxicol, 2022, 109: 93-100. DOI: 10.1016/j.reprotox.2021.12.011. pmid: 34990753
[35]	Khajehnoori S, Zarei F, Mazaheri M, et al. Epidrug modulated expression of miR-152 and miR-148a reverse cisplatin resistance in ovarian cancer cells: an experimental in-vitro study[J]. Iran J Pharm Res, 2020, 19(3): 509-519. DOI: 10.22037/ijpr.2020.15450.13217. pmid: 33680048
[36]	Liu J, Zhang X, Huang Y, et al. MiR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases[J]. Oncol Lett, 2019, 17(2): 1453-1460. DOI: 10.3892/ol.2018.9745. pmid: 30675199
[37]	Sun J, Cai X, Yung MM, et al. MiR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer[J]. Oncogene, 2019, 38(4): 564-580. DOI: 10. 1038/s41388-018-0459-x. pmid: 30166592
[38]	Zou Y, Zhao Z, Wang J, et al. Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway[J]. Int J Biol Sci, 2023, 19(10): 3099-3114. DOI: 10.7150/ijbs.83264. pmid: 37416779
[39]	Ni YL, Chien PJ, Hsieh HC, et al. Disulfiram/copper suppresses cancer stem cell activity in differentiated thyroid cancer cells by inhibiting BMI1 expression[J]. Int J Mol Sci, 2022, 23(21): 13276. DOI: 10.3390/ijms232113276.
[40]	Zhang XL, Sun BL, Tian SX, et al. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1[J]. Eur Rev Med Pharmacol Sci, 2019, 23(9): 3635-3644. DOI: 10.26355/eurrev_201905_17787.
[41]	Peng DJ, Wang J, Zhou JY, et al. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells[J]. Biochem Biophys Res Commun, 2010, 394(3): 600-605. DOI: 10.1016/j.bbrc.2010.03.029.
[42]	Chen Y, Wang L, Zhou J. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance[J]. J Obstet Gynaecol Res, 2019, 45(11): 2243-2254. DOI: 10.1111/jog.14079.
[43]	Zhang S, O'Regan R, Xu W. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics[J]. Cancer, 2020, 126(5): 939-948. DOI: 10.1002/cncr.32672. pmid: 31869450
[44]	Shi Y, Zou Y, Guo Y, et al. Exosomal transfer of miR-548aq-3p confers cisplatin resistance via Med12 downregulation in epithelial ovarian cancer[J]. Am J Cancer Res, 2023, 13(5): 1999-2012.
[45]	Sad LMAE, Mohamed DA, Elanwar NM, et al. CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy[J]. J Cancer Res Ther, 2021, 17(6): 1454-1461. DOI: 10.4103/jcrt.JCRT_480_19. pmid: 34916377
[46]	Yao W, Wang Y, Huang M, et al. MiR-30a-5p enhances cisplatin sensitivity by downregulating RIF1 in ovarian cancer[J]. Ann Clin Lab Sci, 2023, 53(3): 418-426. pmid: 37437929